European Companies Search Engine

EU funding (€8,130,000): Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881 Hor1 Apr 2016 EU Research and Innovation programme "Horizon"

Overview

Text

Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881

The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment. To address these goals, RHAPSODY will bring together prominent European experts, including the leaders of the diabetes-relevant IMI1 projects to identify, validate and characterize causal biomarkers for T2D subtypes and progression. Our plans are built upon: (a) access to large European cohorts with comprehensive genetic analyses and rich longitudinal clinical and biochemical data and samples; (b) detailed multi-omic maps of key T2D-relevant tissues and organs; (c) large expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental approaches; (d) the ability to combine existing and novel data sets through effective data federation and use of these datasets in systems biology approaches towards precision medicine; and (e) expertise in regulatory approval, health economics and patient engagement. These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide.


Funded Companies:

Company name Funding amount
ACADEMISCH ZIEKENHUIS GRONINGEN €54,869
ACADEMISCH ZIEKENHUIS LEIDEN €213,342
Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino €104,743
Centre Hospitalier Regional et Universitaire de Lille €299,296
Centre National de la Recherche Scientifique CNRS €468,923
EBERHARD KARLS UNIVERSITAET TUEBINGEN €389,966
Eli Lilly and Company Ltd. €0.00
Imperial College of Science Technology and Medicine €668,523
Institut de Recherches Servier €0.00
Institut National de la Sante et de la Recherche Medicale €408,745
ITA-SUOMEN YLIOPISTO €244,944
Janssen Pharmaceutica N.V. €0.00
Kobenhavns Universitet €599,151
LIPOTYPE €418,969
Lunds Universitet €993,168
Novo Nordisk A/S €0.00
RIJKSUNIVERSITEIT GRONINGEN €85,389
SANOFI-AVENTIS DEUTSCHLAND GmbH €0.00
SCIPROM Sàrl €23,750
SIB SWISS INSTITUTE OF BIOINFORMATICS €187,500
STICHTING AMSTERDAM UMC €194,983
TECHNISCHE UNIVERSITAET DRESDEN €518,723
The Chancellor, Masters and Scholars of the University of Oxford €251,936
Universita Di Pisa €435,663
UNIVERSITE DE LAUSANNE €124,681
Universite de Lille €0.00
Universite Libre de Bruxelles €439,645
Universite Paris Cite €503,970
University of Dundee €499,121

Source: https://cordis.europa.eu/project/id/115881

The filing refers to a past date, and does not necessarily reflect the current state.

Creative Commons License The visualizations for "ACADEMISCH ZIEKENHUIS GRONINGEN - EU funding (€8,130,000): Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.